Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SHE:002675)
China · Delayed Price · Currency is CNY 12.51
-0.11 (-0.87%)
Sep 10, 2026, 3:04 PM CST
SHE:002675 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 10,406 | 11,330 | 10,077 | 15,115 | 13,655 | 12,659 | |
Market Cap Growth | -23.10% | 12.44% | -33.33% | 10.69% | 7.87% | -20.74% |
Enterprise Value | 11,772 | 12,153 | 10,934 | 15,766 | 13,992 | 13,487 |
Last Close Price | 12.62 | 13.66 | 12.12 | 17.93 | 16.03 | 15.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 51.71 | 57.92 | 54.82 | 72.07 | 44.44 | 83.52 |
Forward PE | 29.35 | 35.92 | 32.62 | 35.79 | 30.39 | 28.05 |
PS Ratio | 3.90 | 4.13 | 3.51 | 4.61 | 3.81 | 3.24 |
PB Ratio | 1.95 | 2.07 | 1.88 | 2.80 | 2.59 | 2.52 |
P/TBV Ratio | 6.30 | 7.18 | 5.83 | 7.51 | 6.23 | 6.91 |
P/FCF Ratio | - | 51.73 | - | - | 22.50 | 30.62 |
P/OCF Ratio | 27.79 | 19.54 | 35.09 | 54.58 | 13.70 | 13.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.42 | 4.43 | 3.81 | 4.81 | 3.91 | 3.45 |
EV/EBITDA Ratio | 20.39 | 22.90 | 25.02 | 30.81 | 20.82 | 18.53 |
EV/EBIT Ratio | 31.27 | 34.51 | 38.69 | 42.18 | 25.36 | 22.00 |
EV/FCF Ratio | - | 55.49 | - | - | 23.05 | 32.62 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.25 | 0.14 | 0.17 | 0.15 | 0.13 | 0.21 |
Debt / EBITDA Ratio | 2.28 | 1.41 | 2.01 | 1.52 | 1.01 | 1.44 |
Debt / FCF Ratio | - | 3.54 | - | - | 1.13 | 2.54 |
Net Debt / Equity Ratio | 0.08 | -0.06 | 0.00 | 0.02 | -0.07 | 0.02 |
Net Debt / EBITDA Ratio | 0.78 | -0.60 | -0.01 | 0.25 | -0.54 | 0.13 |
Net Debt / FCF Ratio | -94.90 | -1.46 | 0.03 | -0.54 | -0.60 | 0.23 |
Asset Turnover | 0.29 | 0.31 | 0.34 | 0.40 | 0.45 | 0.52 |
Inventory Turnover | 2.28 | 2.30 | 1.96 | 1.94 | 2.02 | 2.41 |
Quick Ratio | 1.15 | 1.28 | 1.05 | 0.75 | 0.83 | 0.91 |
Current Ratio | 1.45 | 1.64 | 1.46 | 1.27 | 1.33 | 1.42 |
Return on Equity (ROE) | 3.10% | 2.85% | 2.63% | 4.76% | 6.85% | 5.22% |
Return on Assets (ROA) | 2.59% | 2.46% | 2.11% | 2.87% | 4.36% | 5.09% |
Return on Invested Capital (ROIC) | 5.10% | 4.90% | 3.35% | 5.40% | 8.71% | 8.84% |
Return on Capital Employed (ROCE) | 5.10% | 4.60% | 4.10% | 6.10% | 9.50% | 10.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.93% | 1.73% | 1.82% | 1.39% | 2.25% | 1.20% |
FCF Yield | -0.04% | 1.93% | -1.68% | -1.55% | 4.45% | 3.27% |
Dividend Yield | 0.62% | 0.59% | 0.66% | 0.70% | 0.94% | 0.99% |
Payout Ratio | 76.04% | 56.42% | 118.18% | 123.17% | 81.76% | 199.57% |
Buyback Yield / Dilution | 0.29% | -0.01% | 0.01% | -2.10% | -0.68% | -0.01% |
Total Shareholder Return | 0.91% | 0.58% | 0.67% | -1.40% | 0.25% | 0.98% |